Table 4.
Incidences of BPAR and other outcomes according to TAC-IPV and RM/NRM status in each PRA positive and negative subgroups.
| Low-IPV/NRM | High-IPV/NRM | Low-IPV/RM | High-IPV/RM | P-value | |
|---|---|---|---|---|---|
| PRA positive subgroup | n = 157 | n = 115 | n = 29 | n = 47 | |
| DCGL (n, %) | 7 (4.5%)§ | 11 (9.6%) | 1 (3.4%) | 9 (19.1%)* | 0.008 |
| Overall BPAR (n, %) | 14 (8.9%)§ | 22 (19.1%) | 4 (13.8%) | 14 (29.8%)* | 0.003 |
| Acute TCMR (n, %) | 10 (6.4%) | 17 (14.8%) | 4 (13.8%) | 8 (17.0%) | 0.073 |
| Active ABMR (n, %) | 5 (3.2%)§ | 5 (4.4%)§ | 0 (0.0%) | 9 (19.2%)*† | <0.001 |
| Chronic active TCMR (n, %) | 0 (0.0%) | 1 (0.9%) | 0 (0.0%) | 1 (2.1%) | 0.357 |
| Chronic active ABMR (n, %) | 1 (0.6%) | 3 (2.6%) | 0 (0.0%) | 3 (6.4%) | 0.076 |
| De novo DSA positive (n, %) | 20 (12.7%) | 14 (12.2%) | 1 (3.5%) | 10 (21.3%) | 0.152 |
| CNI toxicity (n, %) | 23 (14.7%) | 20 (17.4%) | 2 (6.9%) | 10 (21.3%) | 0.367 |
| BK virus nephropathy (n, %) | 3 (1.9%) | 7 (6.1%) | 2 (6.9%) | 2 (4.3%) | 0.295 |
| PRA negative subgroup | n = 295 | n = 260 | n = 77 | n = 100 | |
| DCGL (n, %) | 18 (6.1%)§ | 27 (10.4%) | 5 (6.5%) | 19 (19.0%)* | 0.001 |
| Overall BPAR (n, %) | 50 (17.0%)§ | 60 (23.1%) | 15 (19.5%) | 33 (33.0%)* | 0.007 |
| Acute TCMR (n, %) | 43 (14.6%)§ | 49 (18.9%) | 12 (15.6%) | 29 (29.0%)* | 0.012 |
| Active ABMR (n, %) | 8 (2.7%) | 11 (4.2%) | 4 (5.2%) | 6 (6.0%) | 0.447 |
| Chronic active TCMR (n, %) | 6 (2.0%) | 2 (0.8%) | 0 (0.0%) | 0 (0.0%) | 0.202 |
| Chronic active ABMR (n, %) | 4 (1.4%)†§ | 13 (5.0%)* | 0 (0.0%) | 4 (4.0%)* | 0.025 |
| De novo DSA positive (n, %) | 29 (9.8%) | 32 (12.3%) | 11 (14.3%) | 13 (13.0%) | 0.624 |
| CNI toxicity (n, %) | 45 (15.3%) | 38 (14.6%) | 13 (16.9%) | 24 (24.0%) | 0.164 |
| BK virus nephropathy (n, %) | 8 (2.7%) | 11 (4.2%) | 2 (2.6%) | 3 (3.0%) | 0.758 |
Categorical variables are shown as proportions. *P <0.0083 versus low-IPV/NRM group, †P <0.0083 versus high-IPV/NRM group.
ABMR, antibody-mediated rejection; BPAR, biopsy-proven allograft rejection; CNI, calcineurin inhibitor; DCGL, death-censored graft loss; DSA, donor-specific antibody; IPV, intra-patient variability; NRM, non-rapid metabolizer; PRA, panel reactive antibody; RM, rapid metabolizer; TAC, tacrolimus; TCMR, T-cell mediated rejection.